Immune checkpoint inhibitors (ICIs) have substantially improved the prognosis of patients
with different types of cancer. Through blockade of cytotoxic T-lymphocyte antigen 4 (CTLA …

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was first introduced in
2011 by Shoenfeld et al. and encompasses a cluster of related immune mediated diseases …

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death-
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Immune checkpointty inhibitors (ICIs), particularly those targeting programmed death 1 (PD-
1) and anti-programmed death ligand 1 (PD-L1), enhance the antitumor effect by restoring …

Background Immune checkpoint inhibitors combined with chemotherapy as a neoadjuvant
therapy have been applied to the treatment of esophageal squamous cell carcinoma …

Introduction Immune checkpoint inhibitors (ICIs) are effective in treating several cancers;
however, acute kidney injury (AKI) can occur as part as an immune-related adverse event …

Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small
cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can …

Introduction Emerging evidence suggests that the essence of life is the ecological balance of
the neural, endocrine, metabolic, microbial, and immune systems. Gut microbiota have been …

Methods This study used data from an oncologic clinical trial of adaptive dosing combination
ICI therapy in patients with advanced melanoma. Plasma was collected at baseline and 6 …